On September 13, local time, GlaxoSmithKline issued a statement saying that the drug Jideytro achieved a clinically significant 94% objective remission rate in ROS1-positive non-small cell lung cancer patients who were not treated with tyrosine kinase inhibitors in the registered phase I/II Arros-1 trial.

Zhitongcaijing · 4d ago
On September 13, local time, GlaxoSmithKline issued a statement saying that the drug Jideytro achieved a clinically significant 94% objective remission rate in ROS1-positive non-small cell lung cancer patients who were not treated with tyrosine kinase inhibitors in the registered phase I/II Arros-1 trial.